Complain about a product or service

FDA Cracks Down On Cough Medicine For Kids

Hydrocodone not approved for treatment of coughs, colds in children

October 1, 2007

• Vicks Nasal Spray Recalled Due To Bacterial Contamination • FDA Claims Proctor & Gamble Unlawfully Marketing Meds • Start 2009 With a Medicine Cabinet Checkup • Kids Cough Medicine Gets Warning Labels; Critics Not Impressed • Parents Urged To Shun OTC Cough Medicine • Children and Prescription Drug Abuse: The Threat at Home • Feds to Toughen Rules for Over-the-Counter Kids' Cold Medicines • Children Still Taking Dangerous OTC Medicine, Study Finds • Study: Children Should Not Take Antihistamines for Chronic Cough • More Bad News about Cough Medicine • Saline Nasal Wash Improves Children's Cold Symptoms • Cough Medicine Might Not Help Adults, Either • Parents Warned Camphor Can Be Toxic to Children • FDA Warns of Cough, Cold Medicine Risk to Children • Feds Find Kids Getting High On Cough Meds • Honey May Relieve Children’s Cough • Kids’ Cough Medicine Recalled Over Dosing Issue • Kids' Cough & Cold Remedies Under Fire • Drug Companies Withdraw Infant Cold Remedies • Coughs and Colds in Kids: A Doctor's Advice • FDA Cracks Down On Cough Medicine For Kids • FDA Targets Cough Medicine For Kids Under Two • Experts: Skip The Cough Medicine • Despite the Ads, Cough Syrup Does Little Good • FDA Warns Against DXM Abuse --- • More Health News ...

The U.S. Food and Drug Administration says it will take enforcement action against companies marketing cough and pain medications for children that contain hydrocodone.

The agency says the narcotic has not been approved for treatment of coughs and colds in children, though it has been cleared for other, limited uses.

Hydrocodone is one of the strongest medications available to treat pain or to suppress cough. The drug has also been an extremely popular drug of abuse and can lead to serious illness, injury, or death, if improperly used, the FDA said.

Hydrocodone overdose can result in breathing problems or cardiac arrest, and its use may impair motor skills and judgment.

The FDA said it has received reports of medication errors associated with formulation changes in unapproved hydrocodone products and reports of confusion over the similarity of the names of unapproved products to approved drug products. As part of the drug approval process, the agency considers the possibility of medication errors and name confusion.

Some hydrocodone pain-relief products, such as Vicodin, are FDA-approved. However, most of the hydrocodone formulations now marketed to suppress coughs have not been approved. The agency said it is particularly concerned about improper pediatric labeling of unapproved hydrocodone cough suppressants, also known as antitussives, and the risk of medication error involving the unapproved products.

“Companies marketing these unapproved products have not demonstrated the safety and efficacy of these drugs,” said Steven K. Galson, M.D., M.P.H., director of the FDA's Center for Drug Evaluation and Research (CDER).

“A case in point – no hydrocodone cough suppressant has been established as safe and effective for children under 6 years of age and some of these unapproved products carry labels with dosing instructions for children as young as 2 years of age,” Galson said.

The action is part of FDA's broader initiative on the marketing of unapproved drugs that was announced in June 2006.

Alternatives

There are a number of alternatives for patients who might be using unapproved hydrocodone cough suppressants.

There are seven FDA-approved cough suppressant products containing hydrocodone. There also are a variety of approved antitussive products that do not contain hydrocodone. Consumers should consult a health care professional for detailed guidance on treatment options, the agency said.

Anyone marketing unapproved hydrocodone products that are currently labeled for use in children younger than 6 years of age must end further manufacturing and distribution of the products on or before October 31, 2007.

Those marketing any other unapproved hydrocodone drug products must stop manufacturing such products on or before December 31, 2007 and must cease further shipment in interstate commerce on or before March 31, 2008. Further legal action could be taken against those failing to meet these deadlines.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Follow us on Twitter.